.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
Chubb
McKinsey
Express Scripts
Cantor Fitzgerald
Covington
Boehringer Ingelheim
Dow
Novartis
Fuji

Generated: July 28, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 201922

« Back to Dashboard
NDA 201922 describes XIMINO, which is a drug marketed by Sun Pharm Inds Ltd and is included in one NDA. It is available from one supplier. There are seven patents protecting this drug. Additional details are available on the XIMINO profile page.

The generic ingredient in XIMINO is minocycline hydrochloride. There are thirteen drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the minocycline hydrochloride profile page.

Summary for NDA: 201922

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:7
Therapeutic Class:Antibacterials
Dental and Oral Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 201922

Ingredient-typeTetracyclines

Suppliers and Packaging for NDA: 201922

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
XIMINO
minocycline hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL 201922 NDA Ranbaxy Laboratories Inc. 10631-330 10631-330-05 500 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (10631-330-05)
XIMINO
minocycline hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL 201922 NDA Ranbaxy Laboratories Inc. 10631-330 10631-330-06 6 CAPSULE, EXTENDED RELEASE in 1 BLISTER PACK (10631-330-06)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrengthEQ 45MG BASE
Approval Date:Jul 11, 2012TE:RLD:No
Patent:► SubscribePatent Expiration:Apr 2, 2027Product Flag?YSubstance Flag?Delist Request?
Patent:► SubscribePatent Expiration:Jun 24, 2025Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF ACNE
Patent:► SubscribePatent Expiration:Mar 7, 2027Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF ACNE


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Argus Health
Harvard Business School
Express Scripts
Julphar
Deloitte
Citi
Novartis
Baxter
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot